Patients with schizophrenia and type 2 diabetes prescribed GLP-1 receptor agonists were 29% less likely to visit an emergency department for a mental health crisis compared to those not taking GLP-1s, according to a Lancet Psychiatry study

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

In 2022, mental health inpatient Sophie Alderman died after mistakenly believing that the Oxevision camera monitoring system would alert hospital staff to save her.

Mental health nursing expert Jill Archibald provided evidence to the Lampard Inquiry that Oxevision cameras can increase patient paranoia and cause some patients to scream at the device.

The proposed FY26 budget restructuring includes a $1 billion funding reduction affecting community mental health centers, suicide prevention, and substance use treatment programs.

The President's FY26 budget proposed dissolving the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to consolidate them into a new Administration for a Healthy America.

The Substance Abuse and Mental Health Services Administration reinstated $2 billion in mental health and substance use grants on January 14, 2026, following bipartisan pushback.

On January 13, 2026, the Substance Abuse and Mental Health Services Administration terminated hundreds of grants totaling approximately $2 billion for mental health and substance use disorder services.

Proposed FY26 restructuring threatens Health Resources and Services Administration programs that support mental health professional training and health delivery in underserved communities.

On May 12, 2025, the federal administration announced it would not enforce September 2024 Biden-era mental health parity regulations for insurance providers.

The ERISA Industry Committee legally challenged the September 2024 mental health parity rules, claiming the regulations overstepped administrative authority and raised costs.

Study authors proposed bariatric surgery serve as a first-line treatment for clinical obesity, but as a second-line risk-reduction option for preclinical obesity as pharmacotherapy expands.

Clinical obesity prevalence among metabolic bariatric surgery candidates varied across international centers, ranging from 62.7% in the Brazilian cohort to 79.3% in the United Kingdom cohort.

Mean body mass index and distribution across BMI categories (<40, 40-49, and ≥50) did not differ significantly between clinical and preclinical obesity groups within surgical centers.

Study authors noted bariatric surgery in clinical obesity may offer faster economic returns due to reduced post-operative complications, decreased medication use, and fewer hospitalizations.

Bariatric surgery patients with clinical obesity lost modestly less weight post-surgery, trailing preclinical obesity patients by 2 to 4 percentage points in several study cohorts at 12 and 24 months.

Study authors stated bariatric surgery for preclinical obesity should be evaluated as a preventive intervention with longer time horizons and distinct cost-effectiveness thresholds.

Study authors suggested health systems with limited surgical capacity prioritize metabolic bariatric surgery for patients demonstrating clinical obesity-related organ dysfunction.

A Lancet Diabetes & Endocrinology Commission led by Dr. Francesco Rubino in January 2025 proposed separating clinical obesity from preclinical obesity based on organ dysfunction.

Investigators evaluated 2,316 adult gastric bypass and sleeve gastrectomy patients from centers in London, Barcelona, Lille, and São Paulo using the Lancet Diabetes & Endocrinology framework.

Patients with clinical obesity experienced higher baseline American Society of Anesthesiologists surgical risk classifications across all four international study cohorts compared to preclinical obesity patients.